2026 Annual Meeting | Industry Therapeutic Update from Bristol Myers Squibb and Johnson & Johnson Alliance: Unmet Needs in Stroke Prevention for Patients with Atrial Fibrillation and Secondary Stroke: Exploring FXI/FXIa Inhibition

��ɫ��

2026 Annual Meeting | Industry Therapeutic Update from Bristol Myers Squibb and Johnson & Johnson Alliance: Unmet Needs in Stroke Prevention for Patients with Atrial Fibrillation and Secondary Stroke: Exploring FXI/FXIa Inhibition

Date Saturday 04/18/26

Time 06:00 PM - 08:00 PM CDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Gregory W. Albers, MD

Topic(s) General Neurology

Learning Objectives The objective of the BMS/J&J ITU is to address the unmet needs within stroke prevention for patients with atrial fibrillation or secondary stroke.

CME Available No CME available

Event Timeline
06:00 PM - 08:00 PM CDT	Speaker	Industry Therapeutic Update from Bristol Myers Squibb: Addressing Gaps in Stroke Prevention for Atrial Fibrillation and Secondary Stroke: The Evolving Role of FXI/XIa Inhibition

Faculty Disclosures
Pierre Fayad, MD, FAHA, FAAN	Dr. Fayad has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Fayad has received personal compensation in the range of $0-$499 for serving as a Member Data Safety & Monitoring Committee with NINDS.
Gregory W. Albers, MD	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��